Novo Nordisk A/S (NOV.DE)

Xetra · Healthcare · Drug Manufacturers - General
€35.17-0.75%As of 2026-11-22 · EUR
Last session low €34.84Last session high €35.60
52-week low €30.2352-week high €54.87
Market cap (USD)
$170.14B
Sector
Healthcare
P/E (TTM)
10.3x
Dividend yield
4.45%
Next earnings
2027-02-03

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in EUR.

IndicatorValueReading
RSI (14)46.4In the neutral range (30 to 70)
MACD (12, 26, 9)0.22Below its signal line (0.34); histogram -0.11
Bollinger %B (20, 2)28%Inside the bands (34.06 to 38.08)
SMA 2036.07Price is 2.5% below
SMA 5035.23Price is 0.2% below
SMA 20035.91Price is 2.0% below
ATR (20)3.41% of priceAverage true range per day
52-week position20%In the lower part of the 30.23 to 54.87 range

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.

Latest fiscal yearEnded 2025-12-31: revenue of 309.06B DKK and an operating margin of 41.3%.
Next earnings reportExpected on 2027-02-03.

Also listed as NOVO-B.CO (Copenhagen), NVO (NYSE)

More in Drug Manufacturers - General